US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Prurigo Nodularis · Uremic Pruritus · TRVI
Trevi Therapeutics
Trevi Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
195 Church Street, 16th Floor, New Haven, CT 06510, US HQ
2011 Founded
45 Employees
Public company Type
TRVI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 195 Church Street, 16th Floor, New Haven, CT 06510, US
- Founded
- 2011
- Employees
- 45
- Programs
- 11
- Drugs
- 8
- Patents
- 7
Trevi Therapeutics pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Trevi Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
Development asset linked to Trevi Therapeutics in public FDA and regional records.
-
Development asset linked to Trevi Therapeutics in public FDA and regional records.
-
Development asset linked to Trevi Therapeutics in public FDA and regional records.
-
Development asset linked to Trevi Therapeutics in public FDA and regional records.
-
Development asset linked to Trevi Therapeutics in public FDA and regional records.